Health ProductsDear Healthcare Professional Letter

AGRIFLU and FLUAD - Health Canada Lifts the Suspension of Distribution of these Seasonal Flu Vaccines - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs, Biologic/vaccine
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Information on AGRIFLU (Influenza Vaccine, Surface Antigen, Inactivated) and FLUAD (Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1)

November 5, 2012

Subject: Health Canada lifts the suspension of distribution of AGRIFLU® and FLUAD®

Dear Health Care Professional,

Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada would like to inform you that the review of safety information for AGRIFLU® and FLUAD®is now complete and Health Canada has released the two seasonal flu vaccines for immediate use.

Health Canada asked Novartis to stop distribution of AGRIFLU® and FLUAD® as a precautionary measure, while they performed additional testing and reviewed additional data on some particles found in some of the vaccines. These particles were found to be protein aggregates which are predominantly influenza virus-derived (mainly hemagglutinin), which are all normal and necessary components of influenza vaccines. Protein aggregates can occur in the vaccines manufacturing process and do not pose a health risk. Anyone already vaccinated with AGRIFLU® or FLUAD® is not at risk and does not need to be re-vaccinated. This review by Health Canada is now complete and health care professionals in possession of these vaccines can start using them once again.

Please follow the instructions below, prior to administration of AGRIFLU® and FLUAD®:

  • After removing from refrigerator, shake and inspect syringe visually prior to administration.
  • If no particles are visible, you may administer the vaccine.
  • If there are visible particles, allow the vaccine to come to room temperature before use. (AGRIFLU® and FLUAD® can be kept at room temperature (< 25°C) for up to 2 hours as a holding time before injection. This is not a storage recommendation but rather a pre-administration recommendation.)
  • Inspect for any visible particles. If any particles are seen, shake syringe (such material is not uncommon in vaccines and does not pose a health risk). If no particles are visible, you may administer the vaccine.
  • If after completing these steps, visible particles remain, do not use the vaccine.
  • Please follow all other existing administration information as per the Product Monographs.

AGRIFLU® is an inactivated influenza subunit virus vaccine for immunization against influenza, indicated for everyone aged 6 months and older. AGRIFLU® is available in convenient, ready-to-use pre-filled syringes. It has been sold throughout Europe as AGRIPPAL® since 1998.

FLUAD® is an adjuvanted inactivated influenza virus vaccine, specifically indicated in adults 65 years of age and older. FLUAD® contains the adjuvant MF59™, which helps increase antibody production and improve immune response in the elderly. FLUAD® is available in convenient, ready-to-use pre-filled syringes. It has more than 12 years of clinical experience and more than 60 million doses have been distributed worldwide.

Novartis manufactures AGRIFLU® and FLUAD® in Italy and distributes them in Canada by Novartis Pharmaceuticals Canada Inc.

A public communication will be made available on Novartis' website. Please refer to Health Canada's Web site for more information.

Managing marketed health product-related adverse events is dependent upon health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse events in patients receiving AGRIFLU® and FLUAD® should be reported to your local health department in your province/territory or Novartis. More details are provided below:

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.,
Dorval, QC H9S 1A9
e-mail address: drug.safety@novartis.com
Telephone: 1-877-631-6775 EXT. 3425

To correct your mailing address or fax number, contact Novartis Pharmaceuticals Canada Inc.

How to report a suspected Adverse Event following Immunization:
If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form and send it to the local health department in your province or territory.

The Adverse Events Following Immunization Reporting Form and Guidelines can be found on the Public Health Agency of Canada Web site or in the Canadian Compendium of Pharmaceuticals and Specialties.

If you have any questions or have difficulties contacting your local health department, please contact the Vaccine Safety Section at the Public Health Agency of Canada at:
Telephone: 613-954-5590, 1-866-844-0018
Fax: 613-954-9874; 1-866-844-5931

We regret any inconvenience we may have caused during this short period.

Should you require additional medical information regarding the use of AGRIFLU® and FLUAD®, please contact Novartis Medical Information at 1-800-363-8883.

Sincerely,

original signed by

Jean Godin, M.D.
Chief Scientific Officer and Vice-President
Clinical and Regulatory Affairs
Novartis Pharmaceuticals Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime